“Politicians need to finally wake up,” said Lanxess board chariman Matthias Zachert. “In the current phase of economic weakness, the location Germany is not competitive internationally. We urgently need sustainable framework conditions – above all an internationally competitive electricity tariff for the industry, the reduction of excessive bureaucracy and faster approval procedures.”

Lonza has reported 7.7% growth in sales in constant currency terms during 1H 2020 to CHF 3,074 million, with a core EBITDA margin of 29.1%. This, as in 2019, was largely driven by the Lonza Pharma Biotech & Nutrition (LBPN) segment, which had 10.8%3 sales growth and a margin of 34.1%.